Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC by Ezgi B. Ulas, BSc, Sayed M.S. Hashemi, MD, Ilias Houda, MD, Adem Kaynak, MSc, Joris D. Veltman, MD, PhD, Marieke F. Fransen, PhD, Teodora Radonic, MD, PhD, Idris Bahce, MD, PhD

Get full text

First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer u... by Tanja D de Gruijl, Teodora Radonic, Marc C Huisman, Idris Bahce, Johanna E E Pouw, Sayed M S Hashemi, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Suresh Senan, C Willemien Menke-van der Houven van Oordt

Get full text

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study by Tanja D de Gruijl, Lilian J Meijboom, Teodora Radonic, Chris Dickhoff, Idris Bahce, Sayed M S Hashemi, Daniela E Oprea-Lager, Ezgi B Ulas, Suresh Senan, Famke L Schneiders, Joris Veltman, David J Heineman, Anne Vrijmoet, Ilias Houda, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Febe van Maldegem, Marieke F Fransen

Get full text